Methylphenidate Transdermal System
National Institutes of Health
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Abstract▴ The methylphenidate transdermal system (MTS) patch is approved by the US FDA for use in children aged 6–12 years with…
OBJECTIVE: The objective of this selective EBM review is to determine whether or not methylphenidate transdermal system (Daytrana…
The methylphenidate transdermal system (MTS) provides a novel method of delivery for methylphenidate, a well-studied and…
Background: The methylphenidate transdermal system (MTS) is a novel formulation of methylphenidate, a psychostimulant, in an…
Background: The methylphenidate transdermal system (MTS) (Daytrana [Shire Pharmaceuticals Ireland Ltd., Wayne, PA]) has been…
Introduction of the methylphenidate transdermal system (MTS) provides a different way of delivery for the most widely prescribed…
The methylphenidate transdermal system (MTS) is the only nonoral medication approved by the US FDA for treating the symptoms of…
time-limited activities where behavioural impairMethylphenidate Transdermal ment is present (e.g. religious services, sports…
The methylphenidate transdermal system (MTS) patch is approved by the US FDA for use in children aged 6-12 years with attention…